Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: February 17, 2026
Reporting Period: Single event date (February 17, 2026)
Business Context: The registrant is an emerging growth company incorporated in Delaware, trading on the Nasdaq Capital Market. The filing reports a specific corporate event regarding a new clinical case study.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific event and does not contain financial statements or quantitative financial data.
Material Changes
Item 8.01 Other Events: On February 17, 2026, the company issued a press release announcing a new clinical case study. The study demonstrates how the company's CyPath® Lung product supported clinical decision-making in a high-risk patient presenting with multiple pulmonary nodules. No material changes to financial position or operations are reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the clinical utility of CyPath® Lung in a specific high-risk scenario. The full press release is attached as Exhibit 99.1.
Guidance and Risks: The filing text does not provide updated financial guidance, forward-looking statements, or a discussion of risks and contingencies beyond the context of the clinical case study announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for detailed methodology and results of the CyPath® Lung clinical case study.
- Verify the regulatory status and commercial availability of CyPath® Lung in relevant markets.
- Check subsequent filings (10-Q or 10-K) for any financial impact resulting from this clinical validation.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.